Stock Movers Novo Nordisk Down, GSK Departure, Lufthansa Up
Sep 29, 2025
Novo Nordisk faced a downgrade by Morgan Stanley, citing disappointing prescription momentum for its weight-loss drugs. Meanwhile, GSK's CEO Emma Walmsley is stepping down, raising investor concerns over the company's drug pipeline. On a brighter note, Lufthansa announced a strategic plan to improve profitability, which includes cutting 4,000 administrative jobs and targeting significant savings. The financial landscape shifts as these companies navigate challenges and leadership changes.
AI Snips
Chapters
Transcript
Episode notes
Novo Nordisk Faces Prescription And Trial Concerns
- Morgan Stanley downgraded Novo Nordisk to underweight citing weak GLP-1 prescription growth and rising competition.
- The firm also sees low probability for EVOKE trial success testing GLP-1s for Alzheimer’s, adding to recent company headwinds.
Pressure From Management Changes And Tariffs
- Novo Nordisk has had management changes and tariff-related pressure after key ingredients are made in Denmark.
- Despite setbacks, some analysts still rate the stock buy, so sentiment remains mixed.
GSK Leadership Change Sparks Market Hope
- GSK CEO Emma Walmsley will step down and be replaced by chief commercial officer Luke Miels on January 1st.
- Investors welcomed the change as markets bet Miels can rebuild GSK’s drug pipeline and hit long-term sales targets.